Safety and efficacy of liposomal cytarabine in the treatment of neoplastic meningitis

Oncology (Switzerland)

Volumn 89, Issue 3, 2015, Pages 137-142

  Jahn, Franziska ^a   Jordan, Karin ^a   Behlendorf, Timo ^b   Globig, Cordula ^a   Schmoll, Hans Joachim ^a   Müller Tidow, Carsten ^a   Jordan, Berit ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Department of Neurology   (Germany)

Author keywords

Intrathecal chemotherapy; Liposomal cytarabine; Neoplastic meningitis

Indexed keywords

CYTARABINE; DEXAMETHASONE; METHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE; LIPOSOME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BRAIN LYMPHOMA; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CAUDA EQUINA SYNDROME; CEREBROSPINAL FLUID CYTOLOGY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; LEUKOPENIA; LIPOSOMAL DELIVERY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MUCOSA INFLAMMATION; MYELOMA; NAUSEA; NEOPLASTIC MENINGITIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERTIGO; VERY ELDERLY; VOMITING; ADVERSE EFFECTS; COMPLICATION; DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM; PALLIATIVE THERAPY; PROCEDURES; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SPINAL; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MALE; MENINGITIS; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84942197586     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000380913     Document Type: Article

References (24)

1. Gleissner B, Chamberlain MC: Neoplastic meningitis. Lancet Neurol 2006;5: 443-452
2. Chamberlain MC: Neoplastic meningitis. Oncologist 2008;13: 967-977
3. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foa R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006;107: 473-479
4. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH;Medical Research Council/National Cancer Research Institute Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006;108: 465-472
5. Garcia-Marco JA, Panizo C, Garcia ES, Deben G, Alvarez-Larran A, Barca EG, Sancho JM, Penarrubia MJ, Garcia-Cerecedo T, Garcia Vela JA: Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 2009;115: 1892-1898
6. Freilich RJ, Krol G, DeAngelis LM: Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38: 51-57
7. Strother DR, Glynn-Barnhart A, Kovnar E, Gregory RE, Murphy SB: Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J Clin Oncol 1989;7: 1741-1747
8. Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG: Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984;35: 826-830
9. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17: 3110-3116
10. Chamberlain MC, Kormanik P, Howell SB, Kim S: Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995;52: 912-917
11. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB: A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5: 3394-3402
12. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S: Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 2010;116: 2290-2300
13. Feyer P, Sautter-Bihl ML, Budach W, Dunst J, Haase W, Harms W, Sedlmayer F, Souchon R, Wenz F, Sauer R: DEGRO practical guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol 2010;186: 63-69
14. Strik H, Prommel P: Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther 2010;10: 1137-1148
15. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI: Quality-of-life-Adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003;97: 3053-3060
16. Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, Andre C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC: A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 2013;113: 83-92
17. Gaviani P, Corsini E, Salmaggi A, Lamperti E, Botturi A, Erbetta A, Milanesi I, Legnani F, Pollo B, Silvani A: Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. Neurol Sci 2013;34: 2151-2157
18. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB: Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001;84: 157-163
19. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D: Guideline update for MASCC and ESMO in the prevention of chemotherapy-And radiotherapy-induced nausea and vomiting: results of the perugia consensus conference. Ann Oncol 2010;21(suppl 5): v232-v243
20. Chamberlain MC: Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol 2012;109: 143-148
21. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109: 3214-3218
22. Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U: Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol 2011;103: 635-640
23. Falchi L, Gunnellini M, Ferranti L, Liberati AM: High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience. Clin Neurol Neurosurg 2012;114: 1376-1378
24. Chamberlain MC, Glantz MJ: Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;110: 1698, author reply 1698-1699